Want to see TELA full AI Analyst Report?
TELA Bio (TELA) Risk Analysis
Risk Overview Q2, 2026
Source: the company's latest filing for the period ended Jun 30, 2026, filed Aug 11, 2026
Risk Change Over Time
- Debt & Financing - Risk 1Our current cash position, losses, negative cash flows from operations and covenant requirements under our Credit Agreement with Perceptive raise substantial doubt about our ability to continue as a going concern.
To date, we have incurred significant operating losses in each year since our inception and we anticipate that losses may continue for the next several years or until such time as we can generate substantial revenues and achieve profitability. Our Credit Agreement with Perceptive requires compliance with certain financial covenants, including minimum revenue and liquidity thresholds. Our ability to manage our future covenant compliance is dependent in part upon our ability to grow revenue and manage expenses. In connection with the preparation of this Quarterly Report on Form 10-Q for the period ended June 30, 2026, although we were in compliance with these covenants as of June 30, 2026 and we had cash and cash equivalents of $30.4 million, our current forecasts indicate that it is probable that we will not achieve the minimum revenue threshold required under the Credit Agreement for certain future quarterly periods within the twelve month period after June 30, 2026. If we fail to satisfy the minimum revenue covenant, or any other covenant, and do not obtain a waiver or amendment from Perceptive, Perceptive could declare an event of default and accelerate repayment of all outstanding principal and accrued interest under the Credit Agreement, terminate any commitment to extend further credit and foreclose on the collateral granted to it to collateralize such indebtedness. We do not expect to have sufficient liquidity to repay such obligations if repayment were accelerated and therefore there is substantial doubt as to whether we can continue as a going concern for the twelve months from the period ended June 30, 2026. To address these conditions, we are evaluating and pursuing various actions, including seeking a waiver of, or amendment to, the applicable minimum revenue covenant requirements under the Credit Agreement, pursuing strategic initiatives intended to increase revenues, and implementing measures designed to reduce operating expenses. There can be no assurances that we will successfully negotiate such a waiver or amendment on acceptable terms, or at all, or that we will successfully implement adequate strategic initiatives resulting in an increase revenue to or reduction of expenses. Furthermore, our ability to achieve the level of revenue growth necessary to comply with the minimum revenue covenant is dependent on future operating performance and other factors that are not entirely within our control. In addition, the perception that we may not be able to continue as a going concern may impede our ability to pursue strategic opportunities or operate our business due to concerns about our ability to meet our contractual obligations.
Risk Highlights Q2, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 78
- Innovation / R&D - Risk 1Interim "top-line" or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we may publicly disclose interim or preliminary data from our clinical studies, which is based on a initial analysis of then-available data, and the results and related findings and conclusions are subject to change following a full analyses of all data related to the particular trial. We may also make assumptions, estimations, calculations and conclusions as part of our preliminary or topline analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim or preliminary data should be viewed with caution until the final data are available. We may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, study population size, safety database size, interpretations of data or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular current or future product candidate or our business. If the interim or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to use such results to support the marketing of our products may be jeopardized.
- Innovation / R&D - Risk 2We have limited data and experience regarding the safety and efficacy of certain of our products. Results of earlier studies may not be predictive of future clinical trial results, or the safety or efficacy profile for such products.
Our single arm multicenter post-market clinical study, which we refer to as our BRAVO study, was fully enrolled at 92 patients. We conducted this study to support the marketing of our OviTex products for their cleared indicated uses, and currently have limited clinical data for use of our OviTex PRS products in patients. The long-term effects of using certain of our products in a large number of patients have not been studied and the results of short-term clinical use of such products do not necessarily predict long-term clinical benefits or reveal long-term adverse effects. The results of preclinical studies and clinical studies of our products conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials in other patient populations. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials.
- Innovation / R&D - Risk 3Our long-term growth may depend on our ability to enhance our product offerings.
It is important to our business that we continue to enhance our OviTex and OviTex PRS products and develop and introduce new reinforced tissue matrix products and complementary soft -tissue reconstruction solutions. Developing products is expensive and time-consuming and could divert management's attention away from other aspects of our business. The success of any new product offerings or product enhancements to our OviTex and OviTex PRS products will depend on several factors, including our ability to: - properly identify and anticipate surgeon and patient needs;- develop and introduce new products and product enhancements in a timely manner;- avoid infringing upon the intellectual property rights of third parties;- ensure the quality, manufacture and supply of new products by Aroa or other third-party manufacturers we engage;- demonstrate, if required, the safety and efficacy of new products with data from preclinical studies, clinical trials and post-market clinical studies;- obtain the necessary regulatory clearances or approvals for expanded indications, new products or product modifications;- be fully FDA-compliant with marketing of new devices or products;- provide adequate training to potential users of our new products;- receive adequate coverage and reimbursement for procedures performed with our new products; and - develop and expand an effective and dedicated sales and marketing team. If we are not successful in introducing new product indications and developing and commercializing new products and product enhancements, our ability to increase our revenue may be impaired, which could have a material adverse effect on our business, financial condition and results of operations.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.
